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EDITORIAL
Sepsis-associated  acute  kidney injury  --  is it  possible
to move  the  needle  against  this syndrome?,
Lesão  renal  aguda  associada  a  sepse  --  é  possível  fazer  a  diferenc¸a
contra  essa  síndrome?
Prasad Devarajan, Rajit K. Basu ∗
University  of  Cincinnati,  Cincinnati  Children’s  Hospital  Medical  Center,  Center  for  Acute  Care  Nephrology,  Cincinnati,
United States
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lOn  the  one  hand,  sepsis  is  the  leading  cause  of  non-trauma
related  death  in  pediatric  patients  across  the  world,  in  both
developed  and  developing  nations.1 On  the  other  hand,  epi-
demiologic  data  demonstrate  the  independent  contribution
of  acute  kidney  injury  (AKI)  to  morbidity  and  mortality  in
both  adults  and  children.2,3 The  mortality,  morbidity,  and
ﬁnancial  cost  of  AKI  is  signiﬁcant  and  has  led  to  dedicated
global  initiatives  to  eliminate  preventable  AKI  and  mitigate
the  effects  of  existent  AKI.4 Together,  unfortunately,  sepsis
and  AKI  synergize  into  the  ‘‘worst  of  both  worlds’’  --  inciting
a  litany  of  negative  host  responses  and  ultimately  leading
to  poor  patient  outcome.  In  this  issue  of  Jornal  de  Pedia-
tria,  Riyuzo  et  al.5 report  data  on  the  predictive  factors  of
death  in  patients  with  sepsis  associated  AKI.  In  their  retro-
spective  evaluation  of  77  children  with  sepsis  and  AKI,  the
rate  of  severe  AKI  (pRIFLE  stage  I--F  and/or  stage  2--3  were
both  over  75%)  and  the  overall  mortality  rate  was  substantial
(33.7%).
The  drivers  of  injury  and  progression  in  sepsis  and  AKI
are  similar.  Sepsis  is  propagated  by  the  cardinal  mediators
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).f  ischemia,  hypoxia,  inﬂammation,  and  cell  death.  The
ulti-dimensional  pathophysiology  of  sepsis  exerts  pertur-
ations  from  the  cellular  level  to  overall  host  homeostasis.
ata  from  both  animal  and  human  models  supports  dysreg-
lation  of  the  innate  immune  system,  imbalance  of  pro-
nd  anti-inﬂammatory  cytokine  production/degradation,
estabilization  of  apoptotic  pathways,  and  disruption  of
ndothelial  stability.  In  a  parallel  fashion,  AKI  is  typiﬁed
y  a  set  of  host  responses  including  ischemia,  dysregulated
nﬂammation,  hypoxia,  and  renal  tubular  injury.6 Addition-
lly,  AKI  results  in  deleterious  autocrine,  paracrine,  and
ndocrine  cytokine  effects  on  extra-renal  vital  structures
uch  as  the  brain,  heart,  lungs,  and  liver.7 Therefore,  sepsis
nd  AKI,  individually,  are  more  appropriately  characterized
s  syndromes  (versus  ‘‘diseases’’  or  ‘‘injuries’’)  as  they
ead  to  destabilization  of  homeostasis  by  a  variety  of  global
echanisms.
Severe  sepsis-associated  acute  kidney  injury  (SSAKI)  is
ommon,  costly,  and  harmful.  Sepsis  is  the  leading  cause
f  AKI  in  adults  and  children,  accounting  for  33--50%  of
ll  AKI  in  adults  and  25--50%  of  those  in  children.8 As
 uniﬁed  syndrome,  SSAKI  contributes  to  high  mortality,
reater  resource  utilization  (ventilatory  support,  dialysis),
nd  increased  morbidity  for  patients  (increased  length  of
tay).  Additionally,  the  long-term  sequelae  of  SSAKI  are  sig-
iﬁcant;  a notable  proportion  of  surviving  patients  (adults
nd  children)  suffer  chronic  kidney  disease,  early  end-stage
idney  disease,  and  earlier  death.9,10 Unfortunately,  the
athophysiology  of  SSAKI  is  poorly  understood.  Similar  to
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Table  1  Moving  the  needle  for  SSAKI  management.
1. Identiﬁcation  of  patients  and  early  detection  of  injury
A. Recognize  and  treat  sepsis  (early  antibiotics!)
B. Genome-wide  association  studies  (prior  to  illness)
C. Renal  angina  index  driven  biomarker  testing
2. Adjudication  of  injury  progression
A. Biomarker  progression
B. Assessment  of  ‘‘Fluid  Phase’’
3. Supportive  care  and  AKI  bundles
A.  Regular,  daily,  and  hourly  assessments  of  renal
function
B. Optimize  therapy  for  sepsis/hemodynamics
C. AKI  bundles
i.  Reduce  or  eliminate  nephrotoxins
ii. Adjust  medications  for  renal  clearance
4. Next  generation  therapy/targeted  therapeutics
A. Immunomodulation
B. Cell-speciﬁc  targeting  (iron  chelation)
C.  Extracorporeal  devices
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oth  sepsis  and  AKI  (taken  independently),  the  drivers  of
SAKI  include  intrarenal  hemodynamic  changes,  endothe-
ial  dysfunction,  dysregulation  of  inﬂammatory  homeostasis,
ecrosis/apoptosis,  and  ischemic-hypoxic  injury.11 On  a  host
evel,  sepsis  and  AKI  concurrently  propagate  one  another
y  independent  effects  on  systemic  vascular  tone,  inter-
titial  volume,  altered  distribution  of  serum  albumin,  and
nduction  of  nitric  oxide  production.  Separation  of  the  inde-
endent  effects  of  AKI  from  sepsis  has  proven  to  be  difﬁcult,
s  the  two  share  common  pathways  involving  circulatory  dys-
unction,  a  disconnection  of  bio-energetics,  and  stresses  on
he  nitrosative  and  oxidative  pathways.12 Limitations  in  the
bility  of  animal  models  to  replicate  human  disease,  and  a
aucity  of  human  tissue  data,  discredit  the  assumptions  of
epsis  automatically  decreasing  renal  blood  ﬂow  and  leading
o  tubular  necrosis.13 In  both  ‘‘mice  and  men’’,  the  multidi-
ensional  injury  is  potentiated  in  the  very  young  and  very
ld,  and  those  with  chronic  illness.3 For  these  reasons,  sep-
is  and  AKI  go  ‘‘hand-in-hand’’  --  and  likely  synergistically
ontribute  to  the  quick,  downward  spiral  of  patients  suf-
ering  both  injury  syndromes.  Riyuzo  et  al.5 in  their  study
f  children  with  SSAKI,  observed  a  clinical  parallel  to  these
athophysiologic  ﬁndings.  In  their  study,  the  children  with
SAKI  were  young  (median  4  months),  were  diagnosed  early
ﬁrst  day  of  admission  to  the  intensive  care  unit),  and  suf-
ered  severe  injury  (>75%  pRIFLE  class  I--F  and  stage  2--3).
he  independent  risk  factors  associated  with  death  included
haracteristics  of  severely  ill  patients  (mechanical  ventila-
ion,  dialytic  therapy,  and  hypoalbuminemia).  In  their  study,
KI  was  not  independently  associated  with  mortality,  an
nsurprising  ﬁnding  in  the  context  of  the  overall  severe  ill-
ess  of  patients  included  for  study.  Importantly,  no  severity
f  illness  metric  (Pediatric  Risk  of  Mortality,  Pediatric  Index
f  Mortality)  was  included  in  their  study  to  compare  surviving
atients  from  those  who  died.  An  obvious  association  exists,
owever,  between  advanced  kidney  injury  in  patients  with
epsis  (stage  2--3  and/or  the  requirement  of  dialysis)  and
eath  --  supported  by  the  signiﬁcant  decrease  demonstrated
n  the  Kaplan--Meier  survival  estimates.
How  then,  given  the  synergistic  contributions  of  sepsis
nd  AKI,  do  we  move  the  needle  to  improve  outcomes  for
atients  with  SSAKI?  A  multi-faceted,  timely,  rational,  and
ystematic  approach  is  needed  (Table  1).  The  ﬁrst  step  is  the
imely  identiﬁcation  of  patients  at-risk  for  SSAKI.  Obviously
-  treat  the  sepsis!  Early  initiation  of  antibiotics  is  associ-
ted  with  reduced  mortality  --  a  ﬁnding  that  is  only  slowly
eing  appreciated  and  incorporated  into  routine  care  of  crit-
cally  ill  patients.14 Incidental  population  studies  identiﬁed
utative  biomarkers  for  the  purpose  of  identifying  patients
t-risk  of  developing  AKI  (and  the  progression  of  AKI)  in
he  context  of  sepsis.15 Genome-wide  association  studies
GWAS)  carry  the  potential  to  identify  patients  at  high  risk  of
SAKI.16 Meanwhile,  ongoing  animal  studies  identify  newer
iomarkers  for  SSAKI,  speciﬁcally  those  with  potential  for
herapeutic  targeting.  Appropriate  utilization  of  biomark-
rs  in  the  context  of  SSAKI  is  paramount  for  the  inclusion  of
his  next-wave  of  precision  medicine  into  routine  practice.
o  mitigate  capricious  use  of  novel  diagnostic  biomarkers
nd  to  optimize  the  post-test  probability  of  prediction,  the
enal  angina  methodology  of  risk  stratiﬁcation  has  been
erived  and  validated  in  multiple  pediatric  populations.  This
ethodology,  as  cited  by  Riyuzo  et  al.,5 stratiﬁes  patients
n
J
o
ti. Selective  cytopheretic  device
y  risk  and  is  a  facile  system  for  prediction  of  AKI  at  a
ime  after  ICU  admission  (72  h)  carrying  signiﬁcant  rami-
cations  for  patient  management.17--19 The  second  step  is
arly  adjudication  of  the  progression  of  injury.  Biomarkers
or  the  progression  of  SSAKI  may  be  an  important  facet  of
anagement,  particularly  in  the  early  stabilization  phase
f  patients.14 Attention  to  ﬂuid  accumulation  is  paramount.
ncreasing  evidence  from  both  adults  and  children  supports
he  ﬁnding  of  the  deleterious  independent  contribution  of
uid  accumulation  in  critically  ill  patients.20 To  this  end,
uid  management  in  the  SSAKI  patient  population,  inclusive
f  renal  replacement  therapy,  is  important  to  mitigate  the
ffects  of  end-organ  tissue  edema.21 An  important  delin-
ation  must  be  made  with  regards  to  the  ‘‘stage’’  of  ﬂuid
esuscitation  for  a  given  patient;  treating  all  patients  the
ame  and  with  the  same  approach  to  ﬂuid  resuscitation,
tabilization,  and  maintenance  is  nonsensical.22,23 Third,
onsistent  and  systematic  supportive  care  is  paramount.
arly  goal  directed  therapy  for  sepsis  has  become  common-
lace  in  critically  ill  patients,  but  the  notion  of  supportive
are  for  AKI  (regular  assessments  of  creatinine,  attention  to
rine  output  and  weight,  limitations  of  nephrotoxins,  renal
osing  of  medications,  avoidance  of  contrast,  etc.) is  not
onsistent  across  the  globe.  Early  evidence  of  the  introduc-
ion  of  AKI  care  bundles  into  management  is  promising.24
inally,  targeted  therapy  is  on  the  horizon.  Attenuation  of
arly  inﬂammation  using  endocannabinoids  and  cell-based
herapies,  cellular-speciﬁc  targeting  using  iron  chelation
gents,  and  heme-oxygenase  mediators  are  in  advanced
tages  of  clinical  study.25 Extracorporeal  therapies  such  as
he  selective  cytopheretic  device  for  attenuation  of  inﬂam-
ation  may  be  the  next  wave  of  therapy  for  the  most
ritically  ill  patients  with  SSAKI.26
Severe  sepsis  associated  AKI  is  a  combination  of  inde-
endent  and  synergistic  disease  syndromes  with  notable
egative  effects  on  patient  outcome.  In  this  edition  of  the
ornal  de  Pediatria,  Riyuzo  et  al.5 report  just  how  signiﬁcant
f  a  problem  SSAKI  is,  particularly  in  children.  The  inter-
wined  pathophysiology  makes  proper  identiﬁcation  and  risk
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mitigation  for  these  patients  paramount.  Caring  for  these
patients  requires  an  understanding  of  the  importance  of
a  timely,  consistent,  and  multi-dimensional  approach  to
management.
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